NEUROSENSE THERAPEUTICS LTD (NRSN) Stock Price & Overview

NASDAQ:NRSN • IL0011809592

Current stock price

0.8594 USD
+0.01 (+1.11%)
Last:

The current stock price of NRSN is 0.8594 USD. Today NRSN is up by 1.11%. In the past month the price decreased by -14.06%. In the past year, price decreased by -27.17%.

NRSN Key Statistics

52-Week Range0.6801 - 2.6
Current NRSN stock price positioned within its 52-week range.
1-Month Range0.812 - 1.05
Current NRSN stock price positioned within its 1-month range.
Market Cap
28.704M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.54
Dividend Yield
N/A

NRSN Stock Performance

Today
+1.11%
1 Week
-0.76%
1 Month
-14.06%
3 Months
-3.44%
Longer-term
6 Months -29.56%
1 Year -27.17%
2 Years -52.78%
3 Years -50.03%
5 Years N/A
10 Years N/A

NRSN Stock Chart

NEUROSENSE THERAPEUTICS LTD / NRSN Daily stock chart

NRSN Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to NRSN. When comparing the yearly performance of all stocks, NRSN is a bad performer in the overall market: 80.04% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NRSN Earnings

Next Earnings DateMar 25, 2026
Last Earnings DateFeb 26, 2026
PeriodQ2 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

NRSN Forecast & Estimates

9 analysts have analysed NRSN and the average price target is 10.37 USD. This implies a price increase of 1106.66% is expected in the next year compared to the current price of 0.8594.


Analysts
Analysts82.22
Price Target10.37 (1106.66%)
EPS Next Y27.28%
Revenue Next YearN/A

NRSN Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

NRSN Financial Highlights

Over the last trailing twelve months NRSN reported a non-GAAP Earnings per Share(EPS) of -0.54. The EPS increased by 25.92% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-10.21M
Industry RankSector Rank
PM (TTM) N/A
ROA -1037.6%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-292.8%
Sales Q2Q%N/A
EPS 1Y (TTM)25.92%
Revenue 1Y (TTM)N/A

NRSN Ownership

Ownership
Inst Owners0.99%
Shares33.40M
Float27.00M
Ins Owners12.26%
Short Float %1.68%
Short Ratio1.63

NRSN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC14.8388.432B
AMGN AMGEN INC16.04197.413B
GILD GILEAD SCIENCES INC16.4179.993B
VRTX VERTEX PHARMACEUTICALS INC24.21119.226B
REGN REGENERON PHARMACEUTICALS15.9578.843B
ALNY ALNYLAM PHARMACEUTICALS INC42.0141.564B
INSM INSMED INC N/A30.069B
BIIB BIOGEN INC11.2926.644B
NTRA NATERA INC N/A26.624B
UTHR UNITED THERAPEUTICS CORP17.9523.498B
MRNA MODERNA INC N/A20.758B
EXAS EXACT SCIENCES CORP340.7419.77B
RVMD REVOLUTION MEDICINES INC N/A18.798B

About NRSN

Company Profile

NRSN logo image Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Company Info

IPO: 2021-12-09

NEUROSENSE THERAPEUTICS LTD

11 Hamenofim St., Building B

Herzliya IL

Employees: 17

NRSN Company Website

NRSN Investor Relations

Phone: 97297996183

NEUROSENSE THERAPEUTICS LTD / NRSN FAQ

Can you describe the business of NEUROSENSE THERAPEUTICS LTD?

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease


What is the stock price of NEUROSENSE THERAPEUTICS LTD today?

The current stock price of NRSN is 0.8594 USD. The price increased by 1.11% in the last trading session.


Does NEUROSENSE THERAPEUTICS LTD pay dividends?

NRSN does not pay a dividend.


What is the ChartMill rating of NEUROSENSE THERAPEUTICS LTD stock?

NRSN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


Which stock exchange lists NRSN stock?

NRSN stock is listed on the Nasdaq exchange.


What sector and industry does NEUROSENSE THERAPEUTICS LTD belong to?

NEUROSENSE THERAPEUTICS LTD (NRSN) operates in the Health Care sector and the Biotechnology industry.


What is the outstanding short interest for NEUROSENSE THERAPEUTICS LTD?

The outstanding short interest for NEUROSENSE THERAPEUTICS LTD (NRSN) is 1.68% of its float.